19 julio 2017

Zepsyre and Yondelis Effective in BRCA2-Associated Metastatic Breast Cancer .

Published Online: July 18, 2017
AJMC Staff
Resultado de imagen de brca2AN INTERIM ANALYSIS OF TWO phase 2 trials has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer, with 33% clinical response with trabectedin and 61% with lurbinectedin. 

Results of the analysis were reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.

...